244
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents

, , , , , , , , , , , , , , , & show all
Pages 3245-3248 | Received 05 May 2022, Accepted 02 Aug 2022, Published online: 15 Sep 2022
 

Disclosure statement

P.V. has a consulting or advisory role with Blueprint Medicines, Incyte, Abbvie, Jazz Pharmaeuticals, CTI BioPharma Corp, Novarts, Amgen, Pfizer. S.B. has a consulting/advisory role with Syneos Health Independent Data Monitoring Committee. S.W. has a consulting/advisory role with Blueprint Medicines and CTI BioPharma Corp.

Additional information

Funding

No financial support was utilized in the preparation of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.